Patient diagnosed as a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) that is taking the prescribed LDA continuously
Conditions
Interventions
investigational material(s)
Generic name etc : D961H
INN of investigational material :
Therapeutic category code : 232 Agents for peptic ulcer
Dosage and Administration for Investigational material :
Sponsors
AstraZeneca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Provision of written informed consent before starting the study-related procedures and examinations 2. Patients who have the history of gastric and/or duodenal ulcer 3. A diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed LDA during the study treatment period
Exclusion criteria
Exclusion criteria: 1. Having gastric or duodenal ulcer (except for ulcer scar) 2. History of esophageal, gastric or duodenal surgery, except for simple closure of perforation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of gastric or duodenal ulcer | — |
Outcome results
None listed